Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Payables (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Payables for 4 consecutive years, with $318000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables fell 85.18% year-over-year to $318000.0, compared with a TTM value of $318000.0 through Sep 2025, down 85.18%, and an annual FY2024 reading of $4.4 million, up 18.54% over the prior year.
  • Payables was $318000.0 for Q3 2025 at Atara Biotherapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Payables topped out at $12.8 million in Q2 2022 and bottomed at $318000.0 in Q3 2025.
  • Average Payables over 4 years is $5.4 million, with a median of $4.4 million recorded in 2024.
  • The sharpest move saw Payables grew 26.95% in 2024, then crashed 85.18% in 2025.
  • Year by year, Payables stood at $6.9 million in 2022, then tumbled by 46.38% to $3.7 million in 2023, then rose by 18.54% to $4.4 million in 2024, then plummeted by 92.72% to $318000.0 in 2025.
  • Business Quant data shows Payables for ATRA at $318000.0 in Q3 2025, $1.8 million in Q2 2025, and $1.4 million in Q1 2025.